By the same authors

From the same journal

Gene therapy for prostate cancer: Current strategies and new cell-based approaches

Research output: Contribution to journalLiterature review

Published copy (DOI)

Author(s)

  • E J MacRae
  • A Giannoudis
  • R Ryan
  • N J Brown
  • F C Hamdy
  • N Maitland
  • C E Lewis

Department/unit(s)

Publication details

JournalProstate
DatePublished - 1 Apr 2006
Issue number5
Volume66
Number of pages25
Pages (from-to)470-494
Original languageEnglish

Abstract

Prostate cancer is the most commonly diagnosed cancer in adult males in the Western world. It accounts for one in ten cancer cases and is the second leading cause of cancer death in men, after lung cancer. A number of curative treatments are available for patients with localized prostate cancer such as radical prostatectomy, radiotherapy, or brachytherapy. However, a proportion of these men will develop progressive disease, and some will present de novo with advanced and metastatic prostate cancer, which is amenable to palliation only with androgen-withdrawal therapy. Most of these patients will eventually develop hormone refractory disease which is incurable, and for whom gene therapy, if feasible may develop as an alternative treatment option. In this review we discuss the gene therapy vectors and strategies that are currently in use, new cell-based approaches, discuss their advantages and disadvantages, and review the potential or proven pre-clinical and clinical efficacy in prostate cancer models/patients. Prostate 66:470-494,2006. (c) 2005 Wiley-Liss, Inc.

    Research areas

  • gene therapy, prostate cancer, vector, viral, non-viral, macrophage, TUMOR-ASSOCIATED MACROPHAGES, PHASE-I TRIAL, MEMBRANE ANTIGEN PROMOTER/ENHANCER, COLONY-STIMULATING FACTOR, VIRUS THYMIDINE KINASE, CYTOTOXIC T-CELLS, DENDRITIC CELLS, REPLICATION-COMPETENT, RADIATION-THERAPY, DELIVERY-SYSTEM

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations